TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: antibody formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Mutation Burden Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Postvaccination Measles ELISA Antibody Titer ≥120 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Traditional smoking cessation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the number of traditional cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Surface profilometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Phantom Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of gastrointestinal disorders causing diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Renal artery resistive index (RRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adipose cell size distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lens Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom-From-Progression (FFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relative Dose Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion agreeing to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants who complete at least 5 sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of Integrative Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Symptom Score AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Pain in visual analogue scale (VAS score) immediate postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in visual analogue scale (VAS score) 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in visual analogue scale (VAS score) 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in visual analogue scale (VAS score) 1 year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of participants that required opioid consumption
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Fatigue Impact Scale (MFIS) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: composite endpoint of total cardiovascular death, non-fatal myocardial infarction, target vessel revascularization and ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change of pain from before venipuncture to after venipuncture (assessed by children)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain from before venipuncture to after venipuncture (assessed by parents and the observer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No. of mature follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Inferior Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Discomfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported pleasurable opiate effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ApoB 100 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ApoB 48 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indication of excessive toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ribavirin Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raltegravir Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ribavirin Minimum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raltegravir Minimum Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postsurgical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Distance Walked or Wheeled in a Maximum of 10 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Behavioral Intentions to Vape E-cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Behavioral Intentions to Smoke Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Willingness to Vape E-cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Willingness to Smoke Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Showed Clinical Improvement of SSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in airways inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemodynamic repercussions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensory level of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of grade 3-5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of perioperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of completing wedge resection and receiving full dose of stereotactic radiosurgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Performance Quality Rating Scale (PQRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average thickness difference of the RNFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-month outcome rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Locoregional Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Measure the UTI recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Sleeping Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants That Develop Acute Respiratory Illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Japanese Orthopedic Association (JOA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful intubation on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Colonic Transit at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improved neurological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absorbed dose calculation uncertainty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in crying/fussing/irritability episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wave Reflection Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment Emergent Adverse Events Meeting Dose-limiting Toxicity Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiac death, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Social Activity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Candidiasis infection occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Bruch's Membrane Opening - Minimum Rim Area, Global
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to medical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of mitral regurgitation severity by regurgitant volume (RV) and effective regurgitant orifice (ERO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mitral annulus geometry (septal lateral dimension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of adverse events as a measure of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with treatment-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who experience a dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Opioid Consumption Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Benefit of Analgesic Score (OBAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Oxygen Saturation During Activities of Daily Living
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Ventilation During Activities of Daily Living
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Oxygen Consumption During Activities of Daily Living
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Dyspnea Related During Activities of Daily Living
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clearance of RhD-positive red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability as assessed by the collection of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion without new MRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity measured by Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Aggression Intentions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SARS-CoV-2 antibody levels in asymptomatic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 antibody levels in mildly symptomatic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 antibody levels in hospitalized patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Perceptions of School Climate
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: False negative rate of test for colon cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time on Treatment With Afatinib or Chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Severe Immune-related Adverse Events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rapid Visual Information Processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DLT of ipilimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in percentages of T-regs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of steal syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycosylated hemoglobin (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Symptom-free Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative pregnancy rate (CPR)
Endpoint domain: Mortality/survival
Primary endpoint: A/H1N1 HAI Antibody Seroconversion Rate at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: A/H3N2 HAI Antibody Seroconversion Rate at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B/Yamagata HAI Antibody Seroconversion Rate at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B/Victoria HAI Antibody Seroconversion Rate at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: A/H1N1 HAI Antibody Seroconversion Rate at Day 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Availability of Novartis Access medicines at public and private non-profit facilities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Availability of Novartis Access medicines at alternative for-profit drug sellers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Availability of Novartis Access medicines in households with NCD patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective Rating of Overall Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Training effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microassay Tests Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) - Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) - Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sustained virological response (undetectable HCV DNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean forced expiratory volume at one second (FEV1, %pred)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: brain structure and activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-lead electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Focal Electroretinogram Amplitude and Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of Overall Target Plaque Severity Score (OTPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of Reduction in the Need for Second Endoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse Cardiac Side Effects related to Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Infectious Disease Side Effects related to Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Neurological Side Effects related to Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving a score of 3 or 4 on the stages of change questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of skin and gut homing Tregs (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Maximum Temperature ≥37.5°C Reported on the Vaccination Report Card
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card
Endpoint domain: Adverse events/effects
Primary endpoint: Evoked response potential during auditory oddball paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Carotid peak systolic velocity variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic peak systolic velocity variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extravascular water increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNT less than 60 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Reported Outcome Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of HAE Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee MRI results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of MT1MMP, MMP-1,-2 and -9, bradykinin type-2 receptor, AT1 and AT2 receptor, collagen type II and III and collagen breakdown products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age of onset of type 1 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age of onset of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients having complications
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of zoledronic acid doses
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of gastric and/or duodenal bulb lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Magnetic Resonance Imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive neuroscience experiment results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Degree of relief of blepharospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of blepharospasm on daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in International Index of Erectile Function (IIEF) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retinal blood flow increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trimming-induced retinal breaks (TIRB)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Early Virologic Response (cEVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Early Virologic Response (EVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extracellular deposits of beta-amyloid peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of persistent microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in number of experienced celiac-type symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain activation and connectivity response to GABAergic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain electrophysiological activity task-free electroencephalography (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain oscillations under sensory stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thickness of the ganglion cell complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes